Insider track record
OtherNot enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the detailed record of transactions filed by Krishnamohan Neha. Director active across 3 companies, notably Kinnate Biopharma Inc.. Cumulatively, 17 filings have been recorded. Activity tracked since 1 September 2022. The latest transaction was filed on 5 June 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Krishnamohan Neha
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations17 total
5,778 shares0Common StockSEC:0001628280-26-042039:0
27,052 shares@ US$8.63100.0% of flowCommon StockSEC:0001866171-25-000007:0
3,490 shares@ US$3.2579.3% of flowCommon StockSEC:0001193125-25-285005:0
1,341 shares@ US$2.13100.0% of flowCommon StockSEC:0001415889-25-022222:0
7,609 shares0Common StockSEC:0002065881-25-000024:0
60,000 shares0Common StockSEC:0001415889-25-006034:0
50,000 shares0Common StockSEC:0001415889-24-023361:0
10,139 shares0Common StockSEC:0001787306-24-000102:0
64,087 sharesCommon StockSEC:0001415889-24-010431:0
1,506 shares@ US$2.5910.3% of flowCommon StockSEC:0001415889-24-006755:0
1,459 shares@ US$2.258.6% of flowCommon StockSEC:0001209191-23-057455:0
1,459 shares@ US$2.359.0% of flowCommon StockSEC:0001209191-23-048429:0
1,459 shares@ US$4.3016.7% of flowCommon StockSEC:0001209191-23-034447:0
4,375 shares0Common StockSEC:0001787306-23-000052:0
1,721 shares@ US$5.2124.3% of flowCommon StockSEC:0001209191-23-015868:0
1,459 shares@ US$7.7531.0% of flowCommon StockSEC:0001209191-22-059514:0
67,500 shares0Common StockSEC:0001209191-22-048526:0
About Krishnamohan Neha
Krishnamohan Neha has filed 17 disclosures in total. In the recent disclosures held, they span the period from 2022-09-02 to 2026-06-09, with 0 in buys and 0 in sells, and the most common transaction nature is Retenue fiscale. They are associated with Kinnate Biopharma Inc. as CHIEF FINANCIAL OFFICER, with Arcutis Biotherapeutics, Inc. as Director, and with Artiva Biotherapeutics, Inc. as Chief Financial Officer.